New treatment approach improves survival, reduces recurrence risk in muscle-invasive bladder cancer

Дата публикации: 24-07-2026 16:00:05

Researchers have found that a combination of enfortumab vedotin and pembrolizumab helps patients with muscle-invasive bladder cancer live longer while reducing the risk that their cancer will return after surgery, according to an international phase 3 clinical trial published in The New England Journal of Medicine.

Основное содержимое страницы с новостью.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	New Combination Therapy Shows Promise for Advanced Bladder Cancer	0	11.16	06-08-2026
2	FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer	5	5	08-07-2026
3	FDA Approves Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer	0	11.85	10-07-2026
4	Colon cancer breakthrough keeps patients cancer-free for nearly 3 years	0	10.99	06-05-2026
5	Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk Breast Cancer	0	18.85	30-07-2026
6	Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC	0	16.8	11-08-2026
7	Комбинированная терапия рака почки прошла третью фазу клинических испытаний	0	0	01-08-2025
8	Investigators report promising results from Phase II trial of targeted therapy for rare bile duct cancer	7	8	01-07-2026
9	Personalized cancer vaccine shows positive late-stage trial results	0	14.35	19-08-2026
10	Intraperitoneal and Intravenous Paclitaxel Plus S-1 for Gastric Cancer With Peritoneal Metastasis	0	4.7	01-07-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 11.13. Источник: medicalxpress.com.